ClinicalTrials.gg
CompletedNCT01000610Updated Aug 16, 2017Results posted

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Phase 4 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in Tunisia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2008, registered Oct 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
103rd of 113
18 · median 130
Started
2008
with 6 others
Phase 4
38 of 113
3 open now
Registered
42nd of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 103rd largest by enrollment, is one of 7 that started in 2008, is one of 38 in phase 4, and was the 42nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate. Patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and background methotrexate (10-25mg po or sc weekly). After the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated time on study treatment is 1-2 years and target sample size is \<50

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >/= 18 years of age
  • rheumatoid arthritis DAS28 >/= 3.2
  • receiving treatment on an outpatient basis
  • experienced an inadequate response to previous or current treatment with methotrexate

Exclusion criteria

Exclusion Criteria:

  • rheumatic disease other than RA, or significant systemic involvement secondary to RA
  • history of or current inflammatory joint disease other than RA
  • previous treatment with any cell-depleting therapies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    single arm

    Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate · Drug: methylprednisolone

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000 mg iv infusion on days 1 and 15

  • 10-25 mg weekly (oral or parenteral)

  • 100 mg iv prior to each rituximab infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Adverse Events (AEs)

    Time frame: Days 1 and 15, every 8 weeks up to Week 24 and and then every 3 months up to 18 months for a total of 104 weeks

Secondary outcomes

  1. Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity \[visual analog scale: \[VAS\] 0 equals (=) no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to 10. Scores less than (\<) 2.6 indicate best disease control and scores greater than or equal to (≥) 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. The average improvement at each visit to the group score is equal to the formula (Previous DAS28 minus \[-\] current DAS 28)/ Previous DAS 28 x 100. Negative percentages indicate that the participant has worsened in comparison to last evaluation, and positive percentages indicate improvement of its DAS28 score and correlated with a bettering of clinical situation.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24

    The DAS28 score is a measure of the participant's disease activity calculated using the TJC \[28 joints\], SJC \[28 joints\], participant's global assessment of disease activity \[VAS: 0 = no disease activity to 100 = maximum disease activity\] and the ESR for a total possible score of 0 to 10. Scores \< 2.6 indicate best disease control and scores ≥ 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. An improvement of \>1.2 was considered to be clinically significant improvement.

    Time frame: Baseline and Week 24

  3. Change in Bone Density (in Participants Untreated With Bisphosphonates)

    Bone mineral density test was performed using x-ray radiation and the values of bone density were provided directly by the apparatus as grams per square centimeter (g/cm\^2) . T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis.

    Time frame: Screening and Week 84

07

Results

Posted Mar 19, 2015

Participant flow

Participant flow — Overall Study
MilestoneRituximab
Started18
Completed12
Not completed6
Withdrew: Adverse event1
Withdrew: Lost to follow-up4
Withdrew: Treatment failure1

Outcome measures

PrimaryNumber of Participants Reporting Adverse Events (AEs)
Time frame:
Days 1 and 15, every 8 weeks up to Week 24 and and then every 3 months up to 18 months for a total of 104 weeks
Reported as:
Number · number of participants
Number of Participants Reporting Adverse Events (AEs)
number of participantsRituximab
Participants who experienced an AE11
Participants who experienced more than 1 AE7
SecondaryPercentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], participant's global assessment of disease activity \[visual analog scale: \[VAS\] 0 equals (=) no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to 10. Scores less than (\<) 2.6 indicate best disease control and scores greater than or equal to (≥) 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. The average improvement at each visit to the group score is equal to the formula (Previous DAS28 minus \[-\] current DAS 28)/ Previous DAS 28 x 100. Negative percentages indicate that the participant has worsened in comparison to last evaluation, and positive percentages indicate improvement of its DAS28 score and correlated with a bettering of clinical situation.

Time frame:
Baseline and Week 24
Reported as:
Mean · percentage change from baseline
Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24
percentage change from baselineRituximab
Percentage Change in Disease Activity Score 28 (DAS28) From Baseline to Week 24-1.7 ± 49.4
SecondaryPercentage of Participants Whose DAS28 Improved by >1.2 at Week 24

The DAS28 score is a measure of the participant's disease activity calculated using the TJC \[28 joints\], SJC \[28 joints\], participant's global assessment of disease activity \[VAS: 0 = no disease activity to 100 = maximum disease activity\] and the ESR for a total possible score of 0 to 10. Scores \< 2.6 indicate best disease control and scores ≥ 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6. An improvement of \>1.2 was considered to be clinically significant improvement.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Whose DAS28 Improved by >1.2 at Week 24
percentage of participantsRituximab
Percentage of Participants Whose DAS28 Improved by >1.2 at Week 2475.0
SecondaryChange in Bone Density (in Participants Untreated With Bisphosphonates)

Bone mineral density test was performed using x-ray radiation and the values of bone density were provided directly by the apparatus as grams per square centimeter (g/cm\^2) . T-score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as the participant. A T-score with above -1 is normal bone density level. A T-score between -1 and -2.5 means that the bone density is below normal and it might be a sign of an osteopenia and may also lead into osteoporosis. A T-score below -2.5 indicates osteoporosis.

Time frame:
Screening and Week 84
Reported as:
Number · t-score
Change in Bone Density (in Participants Untreated With Bisphosphonates)
t-scoreRituximab
Screening-1.82
Week 84-1.6

Adverse events

Collected over AEs were recorded from the day of first infusion until the End of Study at 104 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—6/18 (33.3%)9/18 (50%)
Most frequent serious events
Most frequent serious events
EventRituximab
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/18
Persistent thrombopeniaBlood and lymphatic system disorders1/18
Rectal bleedingGastrointestinal disorders1/18
Ventricular Extra systolebigeminyCardiac disorders1/18
Severe infusion reactionInjury, poisoning and procedural complications1/18
DyspneaRespiratory, thoracic and mediastinal disorders1/18
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRituximab
HypertensionBlood and lymphatic system disorders2/18
Blurred VisionEye disorders1/18
HyperglycemiaEndocrine disorders1/18
Multi-sensitive Streptococcus CystitisInfections and infestations1/18
Keratitis SeccaSkin and subcutaneous tissue disorders1/18
Red ThroatGeneral disorders1/18
VertigoEar and labyrinth disorders1/18
SomnolenceGeneral disorders1/18
InfluenzaInfections and infestations1/18
Muscular PainMusculoskeletal and connective tissue disorders1/18

Baseline characteristics

Intent-to-Treat (ITT) population: All participants who received any part of an infusion have been included in the ITT analysis. Participants who prematurely withdrew from the study for any reason and for whom an assessment was not performed for whatever reason, were still included in the ITT analyses.

Age, Continuous
Age, Continuous(years)Rituximab
Mean53.4 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female16
Male2
08

Study locations

4 sites
  • Hopital Farhat Hached; Service Rhumatologie
    Sousse, 4000, Tunisia
  • Hopital Charles Nicole; Service Rhumatologie
    Tunis, 1006, Tunisia
  • Hopital La Rabta; Service Rhumatologie
    Tunis, 1007, Tunisia
  • Hopital Mongi Slim; Service Rhumatologie
    Tunis, 2046, Tunisia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2008 to primary completion in May 2012, 49 months.

Results were first posted in Mar 2015, 2 years 10 months after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 49 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2009
First posted
Oct 23, 2009
StartActual
Mar 17, 2008
Primary completionActual
May 16, 2012
CompletionActual
May 16, 2012
Results first posted
Mar 19, 2015
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01000610
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Mar 17, 2008
Primary completion
May 16, 2012
Completion
May 16, 2012
Results posted
Mar 19, 2015
Last update
Aug 16, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion